Adjuvant Chemotherapy in Microsatellite Instability-High Gastric Cancer
4
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Purpose Microsatellite instability (MSI) status may affect the efficacy of adjuvant chemotherapy in gastric cancer. In this study, the clinical characteristics of MSI-high (MSI-H) gastric cancer and the predictive value of MSI-H for adjuvant chemotherapy in large cohorts of gastric cancer patients were evaluated. Materials and Methods This study consisted of two cohorts. Cohort 1 included gastric cancer patients who received curative resection with pathologic stage IB-IIIC. Cohort 2 included patients with MSI-H gastric cancer who received curative resection with pathologic stage II/III. MSI was examined using two mononucleotide markers and three dinucleotide markers. Results Of 359 patients (cohort 1), 41 patients (11.4%) had MSI-H. MSI-H tumors were more frequently identified in older patients (p < 0.001), other histology than poorly cohesive, signet ring cell type (p=0.005), intestinal type (p=0.028), lower third tumor location (p=0.005), and absent perineural invasion (p=0.027). MSI-H status has a tendency of better disease-free survival (DFS) and overall survival (OS) in multivariable analyses (hazard ratio [HR], 0.4; p=0.059 and HR, 0.4; p=0.063, respectively). In the analysis of 162 MSI-H patients (cohort 2), adjuvant chemotherapy showed a significant benefit with respect to longer DFS and OS (p=0.047 and p=0.043, respectively). In multivariable analysis, adjuvant chemotherapy improved DFS (HR, 0.4; p=0.040). Conclusion MSI-H gastric cancer had distinct clinicopathologic findings. Even in MSI-H gastric cancer of retrospective cohort, adjuvant chemotherapy could show a survival benefit, which was in contrast to previous prospective studies and should be investigated in a further prospective trial.
Abstract
Purpose Microsatellite instability (MSI) status may affect the efficacy of adjuvant chemotherapy in gastric cancer. In this study, the clinical characteristics of MSI-high (MSI-H) gastric cancer and the predictive value of MSI-H for adjuvant chemotherapy in large cohorts of gastric cancer patients were evaluated. Materials and Methods This study consisted of two cohorts. Cohort 1 included gastric cancer patients who received curative resection with pathologic stage IB-IIIC. Cohort 2 included patients with MSI-H gastric cancer who received curative resection with pathologic stage II/III. MSI was examined using two mononucleotide markers and three dinucleotide markers. Results Of 359 patients (cohort 1), 41 patients (11.4%) had MSI-H. MSI-H tumors were more frequently identified in older patients (p < 0.001), other histology than poorly cohesive, signet ring cell type (p=0.005), intestinal type (p=0.028), lower third tumor location (p=0.005), and absent perineural invasion (p=0.027). MSI-H status has a tendency of better disease-free survival (DFS) and overall survival (OS) in multivariable analyses (hazard ratio [HR], 0.4; p=0.059 and HR, 0.4; p=0.063, respectively). In the analysis of 162 MSI-H patients (cohort 2), adjuvant chemotherapy showed a significant benefit with respect to longer DFS and OS (p=0.047 and p=0.043, respectively). In multivariable analysis, adjuvant chemotherapy improved DFS (HR, 0.4; p=0.040). Conclusion MSI-H gastric cancer had distinct clinicopathologic findings. Even in MSI-H gastric cancer of retrospective cohort, adjuvant chemotherapy could show a survival benefit, which was in contrast to previous prospective studies and should be investigated in a further prospective trial.
참고문헌 (26)
- Boland CR, "A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition : development of international criteria for the determination of microsatellite instability in colorectal cancer", Cancer Res, 58, pp.5248~5257 (1998)
- Boland CR, "Microsatellite instability in colorectal cancer", Gastroenterology, 138, pp.2073~2087 (2010)
- Yuza K, "Hypermutation and microsatellite instability in gastrointestinal cancers", Oncotarget, 8, pp.112103~112115 (2017)
- Hause RJ, "Classification and characterization of microsatellite instability across 18 cancer types", Nat Med, 22, pp.1342~1350 (2016)
- Buckowitz A, "Microsatellite instability in colorectal cancer is associated with local lymphocyte infiltration and low frequency of distant metastases", Br J Cancer, 92, pp.1746~1753 (2005)
- Marcus L, "FDA approval summary : pembrolizumab for the treatment of microsatellite instability-high solid tumors", Clin Cancer Res, 25, pp.3753~3758 (2019)
- Le DT, "PD-1 blockade in tumors with mismatch-repair deficiency", N Engl J Med, 372, pp.2509~2520 (2015)
- Sargent DJ, "Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer", J Clin Oncol, 28, pp.3219~3226 (2010)
- Gryfe R, "Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer", N Engl J Med, 342, pp.69~77 (2000)
- Costas-Chavarri A, "Treatment of patients with early-stage colorectal cancer : ASCO resource-stratified guideline", J Glob Oncol, 5, pp.1~19 (2019)
- Labianca R, "Early colon cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up", Ann Oncol, 24(Suppl 6), pp.vi64~vi72 (2013)
- Sasako M, "Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer", J Clin Oncol, 29, pp.4387~4393 (2011)
- Noh SH, "Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy(CLASSIC) : 5-year follow-up of an open-label, randomised phase 3 trial", Lancet Oncol, 15, pp.1389~1396 (2014)
- An JY, "Microsatellite instability in sporadic gastric cancer : its prognostic role and guidance for 5-FU based chemotherapy after R0resection", Int J Cancer, 131, pp.505~511 (2012)
- Choi YY, "Microsatellite instability and programmed cell death-ligand 1 expression in stage II", III gastric cancer : post hoc analysis of the CLASSIC randomized controlled study, 2019, pp.270, 309~316
- Pietrantonio F, "Individual patient data meta-analysis of the value of microsatellite instability as a biomarker in gastric cancer", J Clin Oncol, 37, pp.3392~3400 (2019)
- Smyth EC, "Mismatch repair deficiency, microsatellite instability, and survival : an exploratory analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy(MAGIC)trial", JAMA Oncol, 3, pp.1197~1203 (2017)
- Cunningham D, "Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer", N Engl J Med, 355, pp.11~20 (2006)
- Lee J, "Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection : the ARTIST trial", J Clin Oncol, 30, pp.268~273 (2012)
- Bajetta E, "Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer", Ann Oncol, 25, pp.1373~1378 (2014)
- Gavin PG, "Mutation profiling and microsatellite instability in stage II and III colon cancer : an assessment of their prognostic and oxaliplatin predictive value", Clin Cancer Res, 18, pp.6531~6541 (2012)
- Kim ST, "Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy", Cancer Chemother Pharmacol, 66, pp.659~667 (2010)
- Oh SY, "Oncologic outcomes after adjuvant chemotherapy using FOLFOX in MSI-H sporadic stage III colon cancer", World J Surg, 37, pp.2497~2503 (2013)
- Kim JE, "Microsatellite instability was not associated with survival in stage III colon cancer treated with adjuvant chemotherapy of oxaliplatin and infusional 5-fluorouracil and leucovorin(FOLFOX)", Ann Surg Oncol, 24, pp.1289~1294 (2017)
- Oki E, "Chemosensitivity and survival in gastric cancer patients with microsatellite instability", Ann Surg Oncol, 16, pp.2510~2515 (2009)
- Imai K, "Carcinogenesis and microsatellite ins-tability : the interrelationship between genetics and epigenetics", Carcinogenesis, 29, pp.673~680 (2008)